ESR2 and breast carcinoma: Although ERβ was initially associated with breast cancer progression [36,37], a further report studying the intracellular localization of ERβ variants via immunofluorescence in tumor samples provided evidence showing that nuclear expression of ERβ2 and ERβ5 variants correlated with increased overall and disease-free survival [38].